# GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver

> **NCT04546022** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Defense Medical Center, Taiwan** · enrollment: 210 (actual)

## Conditions studied

- Galactose Single Point (GSP), Residual Liver Function

## Interventions

- **DRUG:** Drug: G.S.P. Solution 400 mg/ml I.V. 1.25 ml/kg BW G.S.P. solution after fasting for 6 hours.

## Key facts

- **NCT ID:** NCT04546022
- **Lead sponsor:** National Defense Medical Center, Taiwan
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07-05
- **Primary completion:** 2007-08-12
- **Final completion:** 2018-10-31
- **Target enrollment:** 210 (ACTUAL)
- **Last updated:** 2020-09-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04546022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04546022, "GSP as an Novel Indicator for Residual Liver Function in Patients With Fatty Liver". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04546022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*